Evaluation of 6-([18F]fluoroacetamido)-1-hexanoicanilide for PET imaging of histone deacetylase in the baboon brain

Nuclear Medicine and Biology

Volumn 36, Issue 3, 2009, Pages 247-258

  Reid, Alicia E ^a,b   Hooker, Jacob ^b   Shumay, Elena ^b   Logan, Jean ^b   Shea, Colleen ^b   Kim, Sung Won ^b   Collins, Shanika ^c   Xu, Youwen ^b   Volkow, Nora ^a,d   Fowler, Joanna S ^b  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

^c CITY UNIVERSITY OF NEW YORK   (United States)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

18F FAHA; Histone deacetylase; PET; Pharmacokinetics

Indexed keywords

6 FLUOROACETAMIDO 1 HEXANOICANILIDE F 18; HISTONE DEACETYLASE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BABOON; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; EX VIVO STUDY; IN VITRO STUDY; IN VIVO STUDY; KINETICS; NONHUMAN; RADIOACTIVITY;

ANILIDES; ANIMALS; ARTERIES; BRAIN; CELL LINE, TUMOR; DIFFUSION; ENZYME INHIBITORS; FLUOROACETATES; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INTRACELLULAR SPACE; MODELS, BIOLOGICAL; PAPIO; POSITRON-EMISSION TOMOGRAPHY; RATS; TISSUE DISTRIBUTION;

EID: 62549165162     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.12.005     Document Type: Article

References (36)

1. Peltonen L., and McKusick V.A. Dissecting human disease in the postgenomic era. Science 291 (2001) 1224-1229
2. Egger G., Liang G., Aparicio A., and Jones P. Epigenetics in human diseases and prospects for epigenetic therapy. Nature 429 (2004) 457-463
3. Yang X.J., and Seto E. HATs and HDAC: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26 (2007) 5310-5318
4. Lehrmann H., Pritchard L., and Harel-Bellan. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res 86 (2002) 41-65
5. Jenuwein T., and Allis C.D. Translating the histone code. Science 293 (2001) 1074-1080
6. Weidman J.R., Dolinoy D.C., Murphy S.K., and Jirtle R.L. Cancer susceptibility: epigenetic manifestation of environmental exposures. Cancer J 13 (2007) 9-16
7. De Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., and van Kuilenburg A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370 (2003) 737-749
8. Gray S.G., and Ekstrom T.J. The human histone deacetylase family. Exp Cell Res 262 (2001) 75-83
9. Voelter-Mahlknecht S., Ho A.D., and Mahlknecht U. Chromosomal organization and location of the novel class IV human histone deacetylase 11 gene. Int J Mol Med 16 (2005) 589-598
10. Pan L., Lu J., and Huang B. HDAC Inhibitors: a potential new category of anti-tumor agents. Cell Mol Immun 4 (2007) 337-343
11. Liu T., Kuljaca S., Tee A., and Marshall G. Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 32 (2006) 157-165
12. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature 6 (2006) 38-51
13. Kouraklis G., Misiakos E.P., and Theocharis S. Histone deacetylase inhibitors as a potential therapeutic agent for cancer treatment. Targ Oncol 1 (2006) 34-41
14. Blanchard F., and Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?. Drug Discov Today 10 (2005) 197-204
15. Broide R., Redwine J., Aftahi N., Young W., Bloom F., and Winrow C. Distribution of histone deacetylases 1-11 in the rat brain. J Mol Neurosci 31 (2007) 47-58
16. Bhalla K. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23 (2005) 3971-3993
17. Kazantsev A., and Thompson L. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 7 (2008) 854-868
18. Waltregny D., de Leval, Glenisson W., et al. Expression of histone deacetylase 8, a class 1 histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. Am J Path 165 (2004) 552-564
19. Acharaya M.R., Sparreboom A., Venitz J., and Figg W. Rational development of histone deacetylase inhibitors as anticancer agents: A review. Mol Pharmacol 68 (2005) 917-932
20. Paris M., Porcelloni M., Binaschi M., and Fattori D. Histone deacetylase inhibitors: from bench to clinic. J Med Chem 51 (2008) 1505-1528
21. Miller T.A., Witter D.J., and Belvedere S. Histone deacetylase inhibitors. J Med Chem 46 (2003) 5097-5116
22. Glaser K.B. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 74 (2007) 659-671
23. Blackwell L., Norris J., Suto C.M., and Janzen W.P. The use of diversity profiling to characterize chemical modulators of the histone deacetylases. Life Sci 82 (2008) 1050-1058
24. 18F]FAHA) for PET imaging of histone deacetylase (HDAC). J Label Comp Radiopharm 49 (2006) 997-1006
25. 18F]FAHA. J Nucl Med 48S2 (2007) 34
26. 18F]FAHA). J Nucl Med 48S2 (2007) 336
27. Lear J.L., and Ackerman R.F. Evaluation of radiolabeled acetate and fluoroacetate as potential tracers of cerebral oxidative metabolism. Metab Brain Dis 5 (1990) 45-56
28. 11C-acetate. J Nucl Med 48 (2007) 420-428
29. Perrin D.D., and Armarego W.L. Purification of laboratory chemicals. 3rd ed. (1988), Pergamon Press Inc, New York
30. 14C]carboxy labeled tracers of vorinostat. J Label Comp Radiopharm 49 (2006) 437-443
31. Schueller M., Ferrieri R., and Schlyer D. An automated system for oxygen-18 water recovery and fluorine-18 delivery. Nucl Instrum Methods Phys B: 241 (2005) 660-664
32. 11C-labeled TZTP for imaging muscarinic M2 receptors with PET. Nucl Med Bio 35 (2008) 287-298
33. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10 (1990) 740-747
34. 11C-raclopride binding in the rat brain measured with the microPET R4: effects of scatter correction and tracer specific activity. J Nucl Med 44 (2003) 815-822
35. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23 (2005) 3923-3931
36. Ropero S., Ballestar E., Alaminos M., Arango D., et al. Transforming pathways unleashed by a HDAC2 mutation in human cancer. Oncogene 27 (2008) 4008-4012